Table 3.
Distribution of AFC in the HBOC population, BRCA1 P/LPV carriers and BRCA2 P/LPV carriers compared with the expected nomogram for the general population
| Percentile Distribution in Study Population (HBOC) | Nomogram | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Age | 0–5 | 5–50 | 50–95 | 95–100 | Total | 0–10 | 10–50 | 50–90 | 90–100 | p-value |
| 20–29 | 0 (0%) | 8 (29%) | 9 (32%) | 11 (39%) | 28 (100%) | 10% | 40% | 40% | 10% | 3.36e-6 |
| 30–34 | 0 (0%) | 0 (0%) | 13 (59%) | 9 (41%) | 22 (100%) | 10% | 40% | 40% | 10% | 1.96e-7 |
| ≥35 | 9 (26%) | 7 (20%) | 12 (34%) | 7 (20%) | 35 (100%) | 10% | 40% | 40% | 10% | 0.001 |
| Total | 9 (11%) | 15 (18%) | 34 (40%) | 27 (32%) | 85 (100%) | 10% | 40% | 40% | 10% | 5.11e-11 |
| Percentile Distribution in BRCA1 P/LPV carriers | Nomogram | |||||||||
| 20–29 | 0 (0%) | 3 (27%) | 5 (45%) | 3 (27%) | 11 (100%) | 10% | 40% | 40% | 10% | 0.178 |
| 30–34 | 0 (0%) | 0 (0%) | 4 (44%) | 5 (56%) | 9 (100%) | 10% | 40% | 40% | 10% | 3.63e-5 |
| ≥35 | 3 (25%) | 1 (8%) | 6 (50%) | 2 (17%) | 12 (100%) | 10% | 40% | 40% | 10% | 0.088 |
| Total | 3 (9%) | 4 (13%) | 15 (47%) | 10 (31%) | 32 (100%) | 10% | 40% | 40% | 10% | 0.0001 |
| Percentile Distribution in BRCA2 P/LPV carriers | Nomogram | |||||||||
| 20–29 | 0 (0%) | 5 (31%) | 4 (25%) | 7 (44%) | 16 (100%) | 10% | 40% | 40% | 10% | 0.0001 |
| 30–34 | 0 (0%) | 0 (0%) | 7 (78%) | 2 (22%) | 9 (100%) | 10% | 40% | 40% | 10% | 0.029 |
| ≥35 | 6 (30%) | 5 (25%) | 4 (20%) | 5 (25%) | 20 (100%) | 10% | 40% | 40% | 10% | 0.001 |
| Total | 6 (13%) | 10 (22%) | 15 (33%) | 14 (31%) | 45 (100%) | 10% | 40% | 40% | 10% | 1.89e-5 |
HBOC hereditary breast and/or ovarian cancer, P/LPV pathogenic/likely pathogenic variants.